IRLAB strengthens focus on revenue generation, initiates workforce reductions, and announces reduced likelihood of new partnership agreements in 2026
Gothenburg, Sweden, November 12, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), today announced that the company plans to concentrate its resources on establishing and advancing revenue-generating partnerships based on its current project portfolio. As part of this strategic shift, approximately 10 positions, primarily within early-stage R&D activities, are proposed to be eliminated. This corresponds to approximately 30 percent of the company’s total workforce and remains subject to consultations with the relevant employee representative organizations. The rationale for these measures is that continued investment in the generation of new development projects is currently not expected to create sufficient shareholder value. In addition, the likelihood of entering into new partnership agreements during the current year has decreased, increasing the need for strict cost control. As part of the strategic transformation, the company is recruiting an experienced business development executive for a newly established position as Chief Business Officer (CBO). The measures are expected to reduce the annual cost base by approximately SEK 8 million, with a significant impact expected from Q3 2027 onward.
Read More >
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat and reduce risk of falling and falls in Parkinson’s disease.
Presentation by Kristina Torfgård, CEO, at Redeye’s Theme Event Neurology
Presentation by Kristina Torfgård, CEO, at “Theme Event Neurology”, an event hosted by Redeye, held on October 15, 2026. Link to presentation
Read More >